⌘K

IMNM · Categories · M&A

IMNM - Mergers and acquisitions

Immunome Inc. (IMNM) mergers and acquisitions - real-time wire coverage filtered to M&A only.

Recent M&A for IMNM

805d
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments. "2023 was a transformative year for Immunome as we closed the merger with Morphimmune, advanced our pipeline and expanded the company's leadership team," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "Th

Other IMNM categories